Literature DB >> 21324825

A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure.

Mayer B Davidson1, Philip Raskin, Robert J Tanenberg, Aleksandra Vlajnic, Pricilla Hollander.   

Abstract

OBJECTIVE: To determine whether 1 or 2 preprandial injections before the meals of greatest glycemic impact can be as effective as 3 preprandial injections in patients with type 2 diabetes mellitus and basal insulin treatment failure.
METHODS: This was an open-label, parallel-group, 1:1:1 randomized study of adults with type 2 diabetes mellitus on oral antidiabetic drugs with glycated hemoglobin (A1C) levels of 8.0% or greater. After a 14-week run-in with insulin glargine, patients with an A1C level greater than 7.0% were randomly assigned to 1, 2, or 3 time(s) daily insulin glulisine for 24 weeks. Changes in A1C from randomization to study end; percentage of patients achieving an A1C level less than 7.0%; changes in A1C, fasting glucose concentrations, and weight at individual study points; and safety (adverse events and hypoglycemia) were assessed throughout the study.
RESULTS: Three hundred forty-three of 631 patients (54%) completing the run-in phase with insulin glargine were randomly assigned to treatment arms. During the randomization phase, A1C reductions with insulin glulisine once or twice daily were noninferior to insulin glulisine 3 times daily (confidence intervals: -0.39 to 0.36 and -0.30 to 0.43; P>.5 for both). However, more patients met the target A1C with 3 preprandial injections (46 [46%]) than with 2 injections (34 [33%]) or 1 injection (30 [30%]). Severe hypoglycemia occurred in twice as many patients receiving 3 preprandial injections (16%) compared with those receiving 2 injections (8%) and 1 injection (7%), but these differences did not reach significance.
CONCLUSION: This study provides evidence that initiation of prandial insulin in a simplified stepwise approach is an effective alternative to the current routine 3 preprandial injection basal-bolus approach.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21324825     DOI: 10.4158/EP10323.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  36 in total

1.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

Review 2.  Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.

Authors:  Gerhard H Scholz; Holger Fleischmann
Journal:  Ther Adv Endocrinol Metab       Date:  2014-10       Impact factor: 3.565

3.  Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetologia       Date:  2015-01-13       Impact factor: 10.122

4.  Premixed insulin regimens in type 2 diabetes: pros.

Authors:  Maria Ida Maiorino; Giuseppe Bellastella; Katherine Esposito; Dario Giugliano
Journal:  Endocrine       Date:  2016-03-22       Impact factor: 3.633

Review 5.  The treatment of type 2 diabetes.

Authors:  Andreas F H Pfeiffer; Harald H Klein
Journal:  Dtsch Arztebl Int       Date:  2014-01-31       Impact factor: 5.594

6.  International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.

Authors:  Geremia B Bolli; Larry C Deeb; Satish K Garg; John L Leahy; Roger S Mazze; David R Owens; Matthew C Riddle; Phil Southerland; Ellie S Strock
Journal:  Diabetes Technol Ther       Date:  2011-09       Impact factor: 6.118

Review 7.  Management of Type 2 Diabetes - Methods for Addition of Prandial to Basal Insulin.

Authors:  W Rodbard Helena; Boris Karolicki
Journal:  Eur Endocrinol       Date:  2014-08-25

Review 8.  Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Dario Giugliano; Paolo Chiodini; Maria Ida Maiorino; Giuseppe Bellastella; Katherine Esposito
Journal:  Endocrine       Date:  2015-08-18       Impact factor: 3.633

Review 9.  Insulin therapy for type 2 diabetes.

Authors:  Luigi F Meneghini
Journal:  Endocrine       Date:  2012-10-27       Impact factor: 3.633

Review 10.  Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment.

Authors:  Vivian A Fonseca; Michelle A Haggar
Journal:  Nat Rev Endocrinol       Date:  2014-02-18       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.